24.85

2.17% -0.55

Apellis Pharmaceuticals Inc (APLS)

Overview News Price History Option Chain Financials Why APLS Down? Discussions Forecast

Apellis Pharmaceuticals Inc stock is traded at $24.85, with a volume of 1.69M. It is down -2.17% in the last 24 hours and up +3.97% over the past month. Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Previous Close:

$25.40

Open:

$25.4

24h Volume:

1.69M

Relative Volume:

0.74

Market Cap:

$3.14B

Revenue:

$715.22M

Net Income/Loss:

$-250.10M

P/E Ratio:

-12.24

EPS:

-2.03

Net Cash Flow:

$-205.58M

1W Performance:

-11.66%

1M Performance:

+3.97%

6M Performance:

-1.31%

1Y Performance:

-32.44%

1-Day Range:

$24.79

$25.42

1-Week Range:

$24.79

$28.06

52-Week Range:

$16.10

$38.55

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Name

Apellis Pharmaceuticals Inc

Sector

Healthcare (1152)

Industry

Biotechnology (648)

Phone

617-977-5700

Address

100 FIFTH AVENUE, WALTHAM, KY

Employee

710

Twitter

@ApellisPharma

Next Earnings Date

2024-12-05

Latest SEC Filings

APLS's Discussions on Twitter

Compare APLS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
APLS Apellis Pharmaceuticals Inc	24.85	3.29B	715.22M	-250.10M	-205.58M	-2.03
VRTX Vertex Pharmaceuticals Inc	394.53	99.62B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	465.89	61.52B	2.46B	-319.09M	-52.09M	-2.47
REGN Regeneron Pharmaceuticals Inc	560.00	58.91B	14.21B	4.46B	3.56B	39.68
ARGX Argen X Se Adr	756.38	46.69B	3.06B	1.28B	447.35M	21.30
ONC Beone Medicines Ltd Adr	324.34	34.54B	3.81B	-644.79M	-669.77M	-6.24

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-09-25	Downgrade	BofA Securities	Buy → Neutral
May-09-25	Downgrade	Raymond James	Strong Buy → Outperform
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Dec-17-24	Downgrade	Goldman	Buy → Neutral
Nov-21-24	Initiated	Morgan Stanley	Equal-Weight
Oct-25-24	Initiated	RBC Capital Mkts	Sector Perform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-16-24	Initiated	William Blair	Outperform
May-31-24	Initiated	Piper Sandler	Neutral
Feb-05-24	Upgrade	Jefferies	Hold → Buy
Dec-14-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-09-23	Initiated	Goldman	Buy
Nov-02-23	Initiated	Mizuho	Neutral
Oct-06-23	Upgrade	JP Morgan	Neutral → Overweight
Sep-15-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Aug-29-23	Reiterated	Citigroup	Buy
Aug-03-23	Downgrade	JP Morgan	Overweight → Neutral
Aug-01-23	Downgrade	BofA Securities	Buy → Neutral
Jan-03-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-10-22	Downgrade	Jefferies	Buy → Hold
Jul-19-22	Initiated	H.C. Wainwright	Buy
Jun-17-22	Resumed	Stifel	Buy
Apr-14-22	Downgrade	ROTH Capital	Neutral → Sell
Dec-08-21	Initiated	Wells Fargo	Overweight
Nov-29-21	Downgrade	ROTH Capital	Buy → Neutral
Sep-10-21	Reiterated	BMO Capital Markets	Outperform
Sep-10-21	Reiterated	Credit Suisse	Neutral
Sep-10-21	Reiterated	Needham	Buy
Sep-10-21	Reiterated	Oppenheimer	Outperform
Sep-10-21	Downgrade	Wedbush	Outperform → Neutral
Aug-19-21	Initiated	Jefferies	Buy
Aug-19-21	Upgrade	Wedbush	Neutral → Outperform
May-21-21	Initiated	UBS	Buy
Apr-16-21	Initiated	Goldman	Buy
Nov-19-20	Initiated	Needham	Buy
Sep-01-20	Initiated	Stifel	Buy
Jul-20-20	Initiated	ROTH Capital	Buy
Jun-17-20	Initiated	BTIG Research	Neutral
Apr-01-20	Initiated	Raymond James	Strong Buy
Mar-31-20	Initiated	BMO Capital Markets	Outperform
Mar-11-20	Upgrade	Wedbush	Underperform → Neutral
Jan-07-20	Initiated	SVB Leerink	Mkt Perform
Dec-19-19	Initiated	BofA/Merrill	Buy
Nov-22-19	Initiated	Wedbush	Underperform
Nov-05-19	Initiated	Credit Suisse	Neutral
Aug-01-19	Reiterated	Cantor Fitzgerald	Overweight
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Mar-29-19	Initiated	Robert W. Baird	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Jul-30-18	Upgrade	B. Riley FBR	Neutral → Buy
May-24-18	Initiated	Cantor Fitzgerald	Overweight
Apr-12-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Feb-08-18	Initiated	B. Riley FBR, Inc.	Buy

View All

Apellis Pharmaceuticals Inc Stock (APLS) Latest News

Sep 12, 2025

Focus Partners Advisor Solutions LLC Makes New $363,000 Investment in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat

Sep 12, 2025

When Can We Expect A Profit From Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)? - Yahoo Finance

Sep 12, 2025

Voleon Capital Management LP Buys New Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat

Sep 12, 2025